Table 5.
Serious adverse events reported during second-line therapy
| Everolimus (n = 520) | Sorafenib (n = 240) | Sunitinib (n = 228) | |
|---|---|---|---|
| Serious adverse events, n (%) | 24 (4.6) | 31 (12.9) | 29 (12.7) |
| Types of serious adverse eventsa, n (%) | |||
| Gastrointestinal | 3 (0.6) | 8 (3.3) | 8 (3.5) |
| Haematologic | 2 (0.4) | 3 (1.3) | 8 (3.5) |
| Cardiovascular | 1 (0.2) | 3 (1.3) | 3 (1.3) |
| Metabolic | 2 (0.4) | 6 (2.5) | 1 (0.4) |
| Dermatologic | 2 (0.4) | 9 (3.8) | 1 (0.4) |
| Respiratory | 8 (1.5) | 0 (0.0) | 2 (0.9) |
| Fatigue | 2 (0.4) | 2 (0.8) | 1 (0.4) |
| Other | 5 (1.0) | 6 (2.5) | 5 (2.2) |
aOne patient can have more serious adverse events